You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

King Pharms Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for KING PHARMS, and when can generic versions of KING PHARMS drugs launch?

KING PHARMS has twenty-seven approved drugs.

There is one US patent protecting KING PHARMS drugs.

There are two patent family members on KING PHARMS drugs in two countries and nine supplementary protection certificates in six countries.

Summary for King Pharms
International Patents:2
US Patents:1
Tradenames:25
Ingredients:23
NDAs:27

Drugs and US Patents for King Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms PROCANBID procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 020545-002 Jan 31, 1996 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
King Pharms SKELAXIN metaxalone TABLET;ORAL 013217-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-001 May 25, 2001 AB1,AB3 RX Yes No ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for King Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-002 Jan 28, 1991 5,061,722 ⤷  Try a Trial
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-005 May 25, 2001 7,067,148 ⤷  Try a Trial
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-007 May 25, 2001 7,101,569 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for KING PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 800 mg ➤ Subscribe 2004-11-04
➤ Subscribe Extended-release Capsules 45 mg and 75 mg ➤ Subscribe 2009-07-30
➤ Subscribe Extended-release Capsules 30 mg, 60 mg, 90 mg and 120 mg ➤ Subscribe 2007-06-04

Supplementary Protection Certificates for King Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1539166 SPC/GB13/070 United Kingdom ⤷  Try a Trial PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. Q; REGISTERED: UK EU/1/13/833 20130626
0350733 SPC/GB03/034 United Kingdom ⤷  Try a Trial PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313
1539166 2013C/064 Belgium ⤷  Try a Trial PRODUCT NAME: DEXTROMETHORPHANE OU UN SEL, PRCURSEUR DE DERIVE PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRURE DE DEXTROMETORPHANE ET EN PARTICULIER LE BROMHYDRURE DE DEXTROMETROPHANE MONHYDRATE ET QUINIDINE OU UN SEL,....; AUTHORISATION NUMBER AND DATE: EU/1/13/833 20130626
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.